Key Findings
Tango Therapeutics has announced the development of TNG961, a selective oral HBS1L molecular glue degrader, for the treatment of cancers harboring FOCAD (Folate Cycle Adenosine Deaminase) deletions. Published in Cancer Discovery, an AACR Journal, this first-in-class compound specifically induces translational arrest and demonstrates significant tumor regression in FOCAD-negative preclinical models. This breakthrough establishes a novel precision oncology strategy by exploiting a genetic vulnerability previously challenging to target.
Technical and Clinical Details
TNG961 is a novel small molecule belonging to the class of molecular glues, which operate by stabilizing an interaction between an E3 ubiquitin ligase and a target protein, thereby inducing the target’s degradation via the ubiquitin-proteasome system. In this instance, TNG961 targets the HBS1L-PELO complex. The research revealed that cancer cells deficient in the FOCAD gene are exquisitely dependent on the HBS1L-PELO complex. TNG961’s action—the degradation of this complex—leads to a profound translational arrest within the cell, which is particularly detrimental to FOCAD-negative cancer cells.
Preclinical studies, both in vitro and in vivo, confirmed TNG961’s potent anti-tumor activity in FOCAD-deleted cancers, resulting in robust tumor growth inhibition and regression. A particularly intriguing aspect of this research is the suggestion that TNG961 may also be effective against tumors that have developed resistance to PRMT5 inhibitors. This finding opens up critical therapeutic avenues for patients with cancers that are recalcitrant to current treatment options, addressing a significant unmet medical need.
Background and Context
Precision oncology, which focuses on targeting specific genetic alterations or dependencies in cancer cells, has revolutionized cancer treatment. While FOCAD deletions are known to occur in certain cancer types, directly targeting this vulnerability has been difficult. Tango Therapeutics’ approach leverages the principle of synthetic lethality, where the loss of FOCAD renders cancer cells uniquely susceptible to the disruption of the HBS1L-PELO complex by a molecular glue degrader.
Molecular glue degraders, alongside PROTACs, are at the forefront of the Targeted Protein Degradation (TPD) field. They expand the druggable genome by enabling the targeting of proteins that were previously considered ‘undruggable’ by conventional small molecule inhibitors. The development of TNG961 underscores the power of molecular glues as potent tools for opening new frontiers in personalized cancer medicine.
Strategic Significance and Outlook
The success of TNG961 lays the groundwork for a new cancer treatment strategy that utilizes FOCAD deletion as a predictive biomarker, perfectly aligning with the principles of precision medicine to optimize patient selection and maximize therapeutic efficacy. As TNG961 progresses through clinical trials, it holds the promise of becoming a transformative therapy for patients with FOCAD-deleted cancers, especially those resistant to existing treatments. Furthermore, this research will accelerate the broader development of molecular glue degraders and encourage the exploration of other synthetic lethal targets and challenging cancer indications, impacting future drug discovery efforts significantly.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments